Compare Prudential PLC (PUK) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs GeneDx Holdings Corp — how do they compare? Prudential PLC trades at $23.92 (market cap $28.84B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Prudential PLC is far larger — about 14.3× GeneDx Holdings Corp's market cap, and Prudential PLC pays a 2.33% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential PLC for 119 Days and GeneDx Holdings Corp for 19 Days on average.
| PUK | WGS | |
|---|---|---|
Market Cap | $28.84B | $2.02B |
Volume | 3,531,298 | 734,640 |
Sector | Financials | Health |
52-Week High | $33.61 | $167.51 |
52-Week Low | $23.54 | $34.51 |
Typical Hold Time | 119 Days | 19 Days |
Enterprise Value | $28.38B | $2.05B |
Dividend Yield | 2.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential plc (PUK) trades at $23.88, up 1.44% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $27.39 billion in 2025 and a net income margin of 14.52%, supported by solid profitability metrics. Recent news highlights strategic moves, including the sale of its Alexforbes stake and a rebranding of its U.S. wealth management business to Prudential Wealth Advisors.
The outlook is mixed: attractive valuation ratios and analyst consensus leaning 'Moderate Buy' suggest potential upside, but technical weakness and earnings misses in two of the last four quarters pose near-term risks. Investors should weigh the company's strong cash flow generation and ROE of 19.24% against exposure to macroeconomic volatility and execution of its strategic overhaul.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
